Probi AB
STO:PROB

Watchlist Manager
Probi AB Logo
Probi AB
STO:PROB
Watchlist
Price: 350 SEK -0.28% Market Closed
Market Cap: 4B SEK
Have any thoughts about
Probi AB?
Write Note

Relative Value

The Relative Value of one PROB stock under the Base Case scenario is 192.05 SEK. Compared to the current market price of 350 SEK, Probi AB is Overvalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PROB Relative Value
Base Case
192.05 SEK
Overvaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
44
vs Industry
63
Median 3Y
4.1
Median 5Y
4.8
Industry
7.7
Forward
6.1
vs History
4
vs Industry
1
Median 3Y
53.5
Median 5Y
50.4
Industry
22.7
Forward
94.7
vs History
14
vs Industry
6
Median 3Y
26.1
Median 5Y
26.9
Industry
21.6
vs History
9
vs Industry
2
Median 3Y
44.7
Median 5Y
46.9
Industry
25.2
vs History
49
vs Industry
41
Median 3Y
1.8
Median 5Y
2.2
Industry
2.5
vs History
46
vs Industry
55
Median 3Y
3.6
Median 5Y
4.4
Industry
7.7
Forward
5.7
vs History
30
vs Industry
31
Median 3Y
9.2
Median 5Y
10.6
Industry
9
vs History
11
vs Industry
3
Median 3Y
18.9
Median 5Y
19
Industry
4.2
Forward
31.7
vs History
4
vs Industry
0
Median 3Y
39
Median 5Y
35.4
Industry
4.1
Forward
272.4
vs History
17
vs Industry
5
Median 3Y
22.8
Median 5Y
23.7
Industry
5.7
vs History
9
vs Industry
3
Median 3Y
36.2
Median 5Y
36.2
Industry
3.6
vs History
47
vs Industry
45
Median 3Y
1.9
Median 5Y
2.3
Industry
4.6

Multiples Across Competitors

PROB Competitors Multiples
Probi AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Probi AB
STO:PROB
4B SEK 6.2 291 36.2 922.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
SE
Probi AB
STO:PROB
Average P/E: 222.1
291
190%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
SE
Probi AB
STO:PROB
Average EV/EBITDA: 19.9
36.2
51%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
SE
Probi AB
STO:PROB
Average EV/EBIT: 151.1
922.5
369%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top